SCHEMBL5135970

SCHEMBL5135970

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CCC)Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BCHE P06276 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.43
C5AR1 P21730 1/20 0.42
MMP13 P45452 1/20 0.42
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
DRD2 P14416 3/20 0.39
DRD3 P35462 3/20 0.39
TSHR P16473 1/20 0.39
ALOX5 P09917 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072222 0.96 BCHE (0.50) BCHEL3MBTL1C5AR1MMP13ATP4A
SCHEMBL5136614 0.94 BCHE (0.49) BCHEL3MBTL1C5AR1MMP13ATP4A
SCHEMBL5070125 0.93 L3MBTL1 (0.51) BCHEL3MBTL1C5AR1MMP13ATP4A
SCHEMBL5072351 0.93 ATP4A (0.47) BCHEC5AR1ATP4AATP4BPPARG
SCHEMBL5134715 0.92 C5AR1 (0.44) BCHEC5AR1ATP4AATP4BPPARG
SCHEMBL5135786 0.92 BCHE (0.44) BCHEL3MBTL1C5AR1MMP13ATP4A
SCHEMBL5144498 0.91 BCHE (0.46) BCHEL3MBTL1C5AR1ATP4AATP4B
SCHEMBL5138025 0.90 C5AR1 (0.47) C5AR1TSHR
SCHEMBL5144432 0.89 C5AR1 (0.44) BCHEL3MBTL1C5AR1ATP4AATP4B
SCHEMBL5134649 0.89 C5AR1 (0.44) BCHEC5AR1ATP4AATP4BPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed